BioPharma Convention Australasia - list of speakers

Dr Stephen Barnett is a General Practitioner in Bowral, NSW. His interests focus on the intersection of medical education, health care delivery and information technology. He is currently undertaking a PhD in the role of Virtual Communities of Practice in GP training. Stephen is also the co-founder and medical director of...

In her current role, Michelle is responsible for the oversight of clinical site management of monitoring for Allergan’s clinical trials in Australia and New Zealand. Her involvement extends over into the Asia Pacific Region, with ANZ being a part of the direction of the region. She joined Allergan in April 2008, following a 16 year career in...

Richard graduated from Portsmouth University with a Bachelor of Science (Honours) in Biophysics. He commenced working in the Pharmaceutical Industry in the UK in 1988, took a 3 year break to travel and work in other industries in the early 1990s and has worked in Pharma since his return in 1994, across Sales, Marketing and Training. Richard has...

Donna is Head of Marketing, Haematology, Novartis, Australia & New Zealand and has worked in a variety of sales and marketing management roles in Pharmaceuticals & Biotech, spanning 18 years in the industry (AstraZeneca, Amgen, Schering-Plough, MSD, Novartis). Donna holds a Bachelor of Business majoring in Marketing (UTS) and an MBA (Macquarie...

Harry Collins, is Global Head of Strategy, Business Development & Licensing at Novartis Animal Health, one of the leading Animal Health Companies dedicated to bringing health solutions to veterinarians, livestock producers and pet owners. Harry has 30 years of experience in the Animal Health Industry, working in Australia, USA and Europe and has...

Greg Cook has over 12 years experience within the Australian Pharmaceutical Industry - primarily within the areas of health economics and market access. He is currently the Associate Director, Health Economics at Bristol Myers Squibb, and Chair of the Medicines Australia Health Economics Working Group. Through his Industry and Medicines Australia...

Dr Leigh Farrell was appointed Vice President, Business Development on 24 April 2006. Prior to joining Biota, Dr Farrell spent approximately 4 years as an Associate Director at GBS Ventures Partners Limited, a specialist Life Sciences Venture Capital Fund. Dr Farrell previously held the positions of Research Manager at Johnson & Johnson Research...

Dr Peter French is the Chief Executive Officer of publicly listed (ASX:BLT) gene silencing company Benitec Biopharma Ltd. He has extensive experience in medical research and development spanning 33 years in cell and molecular biology and biotechnology. Peter has an MBA in Technology Management and a PhD in cell biology. He obtained his PhD in...

Dr Joshua Funder joined GBS in 2004 with experience in biotechnology management, business strategy and the international pharmaceutical industry. Before joining GBS Joshua worked in corporate strategy and development at Infinity Pharmaceuticals in Boston and the Boston Consulting Group in San Francisco. In addition he worked with the Clinton...

Dan Grant is the Head of Pfizer’s External Research and Development Innovation (ERDI) group for Australia, New Zealand and Singapore. He is responsible for identifying, evaluating and managing collaborative and licensing opportunities that align with Pfizer’s Worldwide R&D strategies. Dan is also a member of the Pfizer Australia Country Medical ...

Dr Andrew Harvey joined the chemistry group at Bionomics in 2007 and has led the group in the Multiple Sclerosis collaboration with European pharmaceutical company, Merck Serono, since the collaboration began in June 2008. He played a leading scientific role in the partnering discussions with Merck Serono and has inventorship on each of Bionomics...

Carrie is a co-founder of CM Capital and led its Life Sciences group for over 10 years. Her experience ranges from medical research to products on the market and includes mentoring entrepreneurs, assisting with commercialisation and licensing and serving on a number of government, public and private company boards. Carrie is currently chairman of...

Tim is an entrepreneurial academic. Prior to forming Gamma Vaccines in July 2009 he was CEO of ANU Connect Ventures - a pre-seed investment fund. He has also held Senior Executive positions in universities in the United Kingdom and Australia and been a non-executive director of biotech, material science and IT companies.

Jo Kim has had over 20 years experience in the pharmaceutical/biotech industries in Asia Pacific . She started her career as a clinical pharmacist in retail pharmacy and at Westmead Hospital, one of Australia’s largest teaching hospitals based in Sydney where she gained good insight into multidisciplinary team approach to disease management. She...

Kate Lynch was appointed Chief Executive Officer of the Generic Medicines Industry Association (GMiA) in November 2008. The GMiA provides a unified voice representing the interests of the generic prescription medicines industry in Australia. Kate has a wealth of experience working in industry to secure access for new and in line medical products...

Sarah Meibusch is a biotechnology business development consultant experienced in international life science commercialisation. She represents Shire Pharmaceuticals in Australia, New Zealand, Singapore and Taiwan with the aim of identifying new opportunities for Shire collaborations. She currently also holds the position of Deputy Director for the...

With a scientific and financial background, Anthony O’Byrne has been the Advertising Services Manager for the Australian Self-Medication Industry (ASMI) since 2010. ASMI is the peak industry body representing companies involved in the manufacture and distribution of consumer healthcare products. In this role as delegate of the Secretary of the...

Martin has worked in health promotion and health-related PR for his entire professional life. His key strengths are in the areas of healthcare media relations, campaign evaluation, strategy development, social marketing, social media strategy, stakeholder programs and crisis management. He ran health education campaigns for state and Federal...

A/Prof. Sanjoy Paul is the Director of the newly created Queensland Clinical Trials & Biostatistics Centre (QCTBC, http://www.sph.uq.edu.au/qctbc), based at Princess Alexandra Hospital, Brisbane. Dr Paul is a highly skilled clinical trialist and clinical biostatistician with an international reputation. He has a strong methodological background...

Since July 2011 I have been heading Boehringer Ingelheims Nordic eMarketing department, before that I was heading a simular department for Boehringer Ingelheim Denmark. I have worked for Boehringer Ingelheim Denmark since 2006. I started out as a Project Leader for the implementation of CRM ( Siebel ) in the Nordic Countries and continued as the...

Professor Petrovsky is Chairman of Vaxine Pty Ltd, a highly awarded Australian biotech company developing novel vaccine adjuvants. He is a Professor of Medicine at Flinders Medical Centre/Flinders University and Vice-President of the International Immunomics Society. Areas of research include vaccine adjuvants, autoimmunity and immunomics. He...

Dr Ashley Preston is Director of Regulatory Affairs at Takeda Global Research & Development Center Asia, with responsibility for planning and execution of regulatory strategies for pipeline compound development and registration in the APAC region. Prior to Takeda, Ashley worked in regulatory affairs in both the large pharma and biotech...

Mr Pullar is the Market Access / Government Relations Manager of Genzyme in Australasia. He is responsible for coordinating Genzyme’s public affairs and reimbursement activities in Australia and New Zealand. Mr Pullar has worked with Genzyme for over 3 years, creating and implementing market access solutions for a range of innovative and...

I am the Group Leader of the Molecular Mucosal Vaccine Immunology Group, at the Dept of Immunology, The John Curtin School of Medical Research at the ANU. I am a full time researcher and also have research students in my laboratory. I have been working on Mucosal HIV vaccines for just over 10 years.

Associate Professor Craig Rayner has lived and worked in Australia, US, UK and Switzerland gaining 14+ years of extensive international experience in clinical development, scientific due diligence and licensing of pharmaceuticals in academic, clinical, consulting, small biotech and large pharma environments. Within Biotech/Pharma he has had...

Dr Ryan has many years of international experience in the Pharmaceutical/Biotechnology Industry where she managed research and development programs, as well as having key roles in business development and alliance management. Dr Ryan is currently the Vice President, Product Development & Strategic Marketing and oversees the development of products ...

Rob has recently returned to Australia after 16 years working in Asia and the US. Rob is an experienced pharmaceutical/ life sciences executive with 25 years’ + experience in the industry. During his career, Rob has held executive positions with Merck, Astra and a number of entrepreneurial life sciences companies. Rob Is experienced in sales and...

Mark has a PhD in Biochemistry/ Physiology from the University of Sydney and post-graduate qualifications in Health Economics from the University of Newcastle. Following a career as a research scientist Mark moved to the consultancy firm, M-TAG, as a specialist in clinical evaluation and expanded into utility and discrete choice evaluation. He...

Dr. Aamir Shaikh obtained his graduate medical degree (MBBS) in 1992, his post-graduate Diploma in Pharmaceutical Business Management (DPBM) in 1995, and his post-graduate medical degree (MD Pharmacology) in 1997. He began his career as a “Pharmaceutical Physician” with Pfizer India Medical & Research Division in 1998, where he took on the...

Tina is the General Manager for Neuroscience Trials Australia a wholly owned subsidiary of the Florey Neuroscience Institutes. This is a not-for-profit contract research organisation. In this role, Tina is responsible for the overall clinical development of projects on behalf of the institution as well as other academic and commercial sponsors in ...

Dr Andy Stainthorpe PhD leads the Patient Access Scheme and Interventional Procedures programmes for the National Institute for Health and Clinical Excellence (NICE). The programmes are part of the Centre for Health Technology Evaluation the Centre within NICE that produces guidance and advice on medicines, devices and procedures for the NHS. ...

Peter is passionate about innovation and the integration of digital technologies in multichannel marketing and how they can be leveraged with traditional channels to increase customer interaction, brand engagement and return on investment. His experience has been gained working for leading communication agencies such as Mojo and Singleton Ogilvy...

Robert Stringer (B.Pharm. (Hons)) is a pharmacist with more than 15 years of experience in the Australia Pharmaceutical industry. Prior to establishing Capital K Consulting, Robert was the part of the leadership team at AstraZeneca Australia, having managed the Regulatory Affairs, Clinical Research and Strategic Planning & Business Development...

Veronique Toully joined UCB in 2004 and has been appointed as Managing Director for UCB Australia in February 2010. Veronique has over 20 years experience in the pharmaceutical and biotech industry. She started her career in R&D and prior joining UCB had 10 years consulting experience in the area of pricing and reimbursement for drugs and medical...

Mr Woolf is an accomplished biotechnology professional with 18 years’ experience in the industry, equity research and investment banking. He was formerly Chief Business Officer and Executive Director of Oxford BioMedica, a London-listed biotechnology company. Previously, he was Head of European Biotechnology Research at ABN Amro and he has held...